Header Logo

Parameswaran Venugopal

Concepts (236)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
244
1.840
Why?
Lymphoma, Non-Hodgkin
8
2019
36
1.190
Why?
Leukemia, Myeloid, Acute
5
2021
51
1.170
Why?
Arabinonucleosides
4
2021
7
0.960
Why?
Lymphoma
3
2023
35
0.950
Why?
Antibodies, Monoclonal
8
2011
176
0.950
Why?
Lymphoma, Large B-Cell, Diffuse
6
2019
36
0.940
Why?
Central Nervous System Neoplasms
3
2023
11
0.940
Why?
Rituximab
16
2023
48
0.920
Why?
Antineoplastic Agents
5
2022
197
0.780
Why?
Antibodies, Monoclonal, Murine-Derived
11
2017
30
0.750
Why?
Adenine Nucleotides
2
2010
3
0.680
Why?
Burkitt Lymphoma
3
2021
7
0.550
Why?
Paraproteinemias
2
2019
4
0.540
Why?
Insulin-Like Growth Factor Binding Proteins
1
2015
10
0.480
Why?
Middle Aged
25
2023
8887
0.460
Why?
Insulin-Like Growth Factor I
1
2015
59
0.460
Why?
Adult
21
2021
7793
0.440
Why?
Humans
43
2023
26946
0.440
Why?
Treatment Outcome
18
2021
3454
0.440
Why?
Aged
22
2023
8979
0.420
Why?
Male
25
2022
14718
0.390
Why?
Cyclophosphamide
9
2021
48
0.380
Why?
Necrobiotic Xanthogranuloma
1
2011
1
0.380
Why?
Plasma Cells
1
2011
5
0.380
Why?
Mediastinum
1
2011
6
0.380
Why?
Lymphoma, Mantle-Cell
1
2011
3
0.370
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2022
16
0.360
Why?
Female
26
2021
15166
0.350
Why?
Doxorubicin
7
2021
57
0.340
Why?
Arsenicals
2
2007
12
0.340
Why?
Oxides
2
2007
16
0.330
Why?
Cranial Irradiation
2
2007
12
0.330
Why?
Aged, 80 and over
11
2023
4771
0.330
Why?
Vincristine
7
2019
23
0.320
Why?
Prednisone
7
2019
66
0.310
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
9
0.300
Why?
Cachexia
2
2019
12
0.300
Why?
Disease-Free Survival
7
2021
174
0.290
Why?
Kaplan-Meier Estimate
5
2021
175
0.290
Why?
Leukemia, Myelomonocytic, Acute
1
2007
1
0.280
Why?
Sarcoma, Myeloid
1
2007
4
0.280
Why?
Ear Neoplasms
1
2007
7
0.280
Why?
Lymphoproliferative Disorders
2
2023
15
0.280
Why?
Brain Neoplasms
2
2006
86
0.270
Why?
Recurrence
6
2020
306
0.260
Why?
Epstein-Barr Virus Infections
2
2023
11
0.260
Why?
HIV Infections
2
2021
466
0.260
Why?
Purpura, Thrombotic Thrombocytopenic
1
2006
10
0.250
Why?
Drug Administration Schedule
6
2019
158
0.250
Why?
Biomarkers
3
2019
561
0.240
Why?
Combined Modality Therapy
4
2019
299
0.240
Why?
Immunotherapy
2
2008
57
0.230
Why?
Prognosis
6
2021
781
0.230
Why?
Lymphomatoid Granulomatosis
1
2003
2
0.220
Why?
Lymphoma, B-Cell
3
2008
10
0.210
Why?
Proto-Oncogene Proteins c-myc
2
2021
16
0.200
Why?
Remission Induction
6
2015
90
0.190
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
3
2011
19
0.180
Why?
Drug Resistance, Neoplasm
3
2020
69
0.180
Why?
Thrombosis
1
2021
54
0.180
Why?
Deubiquitinating Enzymes
1
2020
1
0.170
Why?
Benzylidene Compounds
1
2020
1
0.170
Why?
Azepines
1
2020
3
0.170
Why?
Multiple Myeloma
1
2020
19
0.170
Why?
Retrospective Studies
5
2023
3522
0.160
Why?
Folic Acid Deficiency
1
2019
7
0.160
Why?
Phthalazines
1
2019
6
0.160
Why?
Graft vs Host Disease
1
2020
54
0.160
Why?
Respiratory Insufficiency
1
2020
51
0.160
Why?
Central Nervous System
3
2023
55
0.160
Why?
Young Adult
4
2021
1984
0.160
Why?
Proportional Hazards Models
2
2017
346
0.160
Why?
Proto-Oncogene Proteins c-bcl-2
1
2019
21
0.160
Why?
Hematopoietic Stem Cell Transplantation
1
2020
109
0.150
Why?
Neutropenia
4
2012
16
0.150
Why?
Piperazines
1
2019
85
0.150
Why?
Cytosine
2
2021
5
0.150
Why?
Kidney Diseases
1
2019
71
0.150
Why?
Neoplasm Recurrence, Local
3
2021
205
0.150
Why?
Medical Oncology
1
2018
44
0.150
Why?
Cardiology
1
2018
44
0.140
Why?
Immunity
1
2017
15
0.140
Why?
Bendamustine Hydrochloride
1
2016
6
0.140
Why?
Immunocompromised Host
1
2017
46
0.130
Why?
Stroke Volume
1
2016
54
0.130
Why?
Biopsy
2
2019
201
0.130
Why?
Registries
1
2017
188
0.130
Why?
Feasibility Studies
2
2019
219
0.120
Why?
Induction Chemotherapy
1
2015
13
0.120
Why?
Hematologic Neoplasms
1
2014
17
0.110
Why?
Myelodysplastic Syndromes
2
2004
33
0.110
Why?
Metabolic Syndrome
1
2014
58
0.110
Why?
Herpesvirus 4, Human
2
2023
7
0.110
Why?
Leukopenia
2
2011
7
0.110
Why?
Lymphoma, Follicular
2
2011
4
0.110
Why?
Methotrexate
2
2023
38
0.100
Why?
Transcription Factors
2
2004
169
0.100
Why?
Cytarabine
3
2023
11
0.100
Why?
Daunorubicin
2
2015
5
0.100
Why?
Diabetes Mellitus, Type 2
1
2014
167
0.100
Why?
Hemoglobinuria, Paroxysmal
1
2012
2
0.100
Why?
Transcriptome
1
2012
87
0.100
Why?
DNA-Binding Proteins
2
2004
276
0.100
Why?
Agranulocytosis
1
2011
4
0.090
Why?
Obesity
1
2014
310
0.090
Why?
Lymphoma, B-Cell, Marginal Zone
1
2011
5
0.090
Why?
Yttrium Radioisotopes
1
2011
10
0.090
Why?
Fatal Outcome
2
2008
54
0.090
Why?
Cytokines
1
2012
221
0.090
Why?
Retreatment
1
2010
8
0.090
Why?
Salvage Therapy
1
2010
35
0.090
Why?
Pilot Projects
1
2011
417
0.080
Why?
Platelet Count
2
2007
16
0.080
Why?
Infusions, Intravenous
2
2020
52
0.070
Why?
Tomography, X-Ray Computed
1
2011
683
0.070
Why?
Tretinoin
1
2007
15
0.070
Why?
Injections, Spinal
1
2007
33
0.070
Why?
Weight Loss
2
2019
127
0.070
Why?
Severity of Illness Index
2
2021
877
0.070
Why?
Vascular Neoplasms
1
2006
4
0.070
Why?
ADAMTS13 Protein
1
2006
5
0.060
Why?
Plasma Exchange
1
2006
12
0.060
Why?
Follow-Up Studies
1
2011
1784
0.060
Why?
Hemoglobins
1
2006
33
0.060
Why?
ADAM Proteins
1
2006
40
0.060
Why?
Immunosuppressive Agents
2
2023
120
0.060
Why?
Autoantibodies
1
2006
80
0.060
Why?
Survival Analysis
2
2019
256
0.060
Why?
Twins, Dizygotic
1
2005
3
0.060
Why?
Radiography
1
2007
616
0.060
Why?
United States
2
2021
2034
0.060
Why?
Kidney Transplantation
1
2006
119
0.060
Why?
Proto-Oncogenes
1
2004
4
0.060
Why?
Thalidomide
1
2004
7
0.060
Why?
Cohort Studies
2
2021
1882
0.060
Why?
Etoposide
2
2019
27
0.060
Why?
Peripheral Blood Stem Cell Transplantation
1
2004
1
0.060
Why?
Antigens, CD20
1
2003
4
0.060
Why?
Epilepsy, Tonic-Clonic
1
2003
4
0.060
Why?
Vision Disorders
1
2003
20
0.050
Why?
Antigens, Neoplasm
1
2003
41
0.050
Why?
Cyclin D1
1
2003
5
0.050
Why?
Cell Cycle Proteins
1
2003
17
0.050
Why?
K562 Cells
1
2003
3
0.050
Why?
Telomerase
1
2003
10
0.050
Why?
Histones
1
2003
32
0.050
Why?
Cerebral Cortex
1
2003
155
0.050
Why?
Apoptosis
1
2003
212
0.050
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2022
1
0.050
Why?
Voriconazole
1
2022
12
0.050
Why?
Sulfonamides
1
2022
37
0.050
Why?
Risk Factors
2
2005
2295
0.050
Why?
Azacitidine
1
2021
10
0.050
Why?
United Kingdom
1
2021
47
0.050
Why?
L-Lactate Dehydrogenase
1
2021
6
0.050
Why?
Gene Rearrangement
1
2021
10
0.050
Why?
Incidence
1
2023
758
0.040
Why?
Thrombocytopenia
2
2012
21
0.040
Why?
Anemia
2
2012
34
0.040
Why?
Postoperative Complications
1
2006
911
0.040
Why?
Folic Acid
1
2019
21
0.040
Why?
Monoclonal Gammopathy of Undetermined Significance
1
2019
2
0.040
Why?
Kidney Function Tests
1
2019
15
0.040
Why?
Maintenance Chemotherapy
1
2019
1
0.040
Why?
Translocation, Genetic
1
2019
5
0.040
Why?
Immunoglobulin A
1
2019
14
0.040
Why?
Maximum Tolerated Dose
1
2019
13
0.040
Why?
Symptom Assessment
1
2019
19
0.040
Why?
Activities of Daily Living
1
2023
595
0.040
Why?
Transplantation, Homologous
1
2020
267
0.040
Why?
Vidarabine
2
2011
9
0.040
Why?
Sarcopenia
1
2019
31
0.040
Why?
Body Composition
1
2019
68
0.040
Why?
Interdisciplinary Communication
1
2018
17
0.040
Why?
Magnetic Resonance Imaging
1
2003
1106
0.040
Why?
Cardiologists
1
2018
7
0.040
Why?
Mitoxantrone
2
2011
4
0.040
Why?
Lung Neoplasms
1
2003
551
0.040
Why?
Ovarian Neoplasms
1
2019
72
0.040
Why?
Disease Management
1
2019
102
0.040
Why?
Bortezomib
1
2017
3
0.040
Why?
Sex Factors
1
2019
461
0.040
Why?
Tomography, Emission-Computed
2
2006
10
0.030
Why?
Disease Progression
2
2012
673
0.030
Why?
Prospective Studies
2
2015
1771
0.030
Why?
Recombinant Proteins
2
2008
178
0.030
Why?
Neoplasms
1
2019
237
0.030
Why?
Adolescent
1
2021
2156
0.030
Why?
Naphthalimides
1
2015
1
0.030
Why?
Organophosphonates
1
2015
1
0.030
Why?
Adenine
1
2015
3
0.030
Why?
Sensitivity and Specificity
2
2006
479
0.030
Why?
Lipid Metabolism
1
2014
38
0.030
Why?
Insulin Resistance
1
2014
50
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2004
137
0.030
Why?
Cytogenetic Analysis
1
2012
6
0.030
Why?
Administration, Oral
1
2012
108
0.020
Why?
RNA, Messenger
2
2003
310
0.020
Why?
Signal Transduction
1
2014
443
0.020
Why?
Pneumonia
1
2012
67
0.020
Why?
Radiopharmaceuticals
1
2011
51
0.020
Why?
Time Factors
1
2015
1429
0.020
Why?
Nausea
1
2007
24
0.020
Why?
Methylprednisolone
1
2007
20
0.020
Why?
Creatinine
1
2007
42
0.020
Why?
Cisplatin
1
2007
58
0.020
Why?
Animals
1
2014
3627
0.020
Why?
Dose-Response Relationship, Drug
1
2006
333
0.020
Why?
MDS1 and EVI1 Complex Locus Protein
1
2004
3
0.010
Why?
Zinc Fingers
1
2004
12
0.010
Why?
Cell Lineage
1
2004
24
0.010
Why?
Spleen
1
2004
30
0.010
Why?
Teniposide
1
2004
1
0.010
Why?
Bleomycin
1
2004
2
0.010
Why?
Interferon-alpha
1
2004
26
0.010
Why?
Drug Therapy, Combination
1
2004
161
0.010
Why?
Patient Selection
1
2005
192
0.010
Why?
Neoplasm Staging
1
2005
362
0.010
Why?
Transplantation, Autologous
1
2004
151
0.010
Why?
E2F Transcription Factors
1
2003
5
0.010
Why?
S Phase
1
2003
11
0.010
Why?
E2F1 Transcription Factor
1
2003
5
0.010
Why?
Retinoblastoma Protein
1
2003
11
0.010
Why?
Karyotyping
1
2003
11
0.010
Why?
Granulocytes
1
2003
15
0.010
Why?
DNA Primers
1
2003
52
0.010
Why?
In Situ Hybridization, Fluorescence
1
2003
36
0.010
Why?
Bone Marrow Cells
1
2003
51
0.010
Why?
Cell Nucleus
1
2003
83
0.010
Why?
Blotting, Western
1
2003
147
0.010
Why?
Transcription, Genetic
1
2003
107
0.010
Why?
Polymerase Chain Reaction
1
2003
120
0.010
Why?
Bone Marrow
1
2003
75
0.010
Why?
Acute Disease
1
2003
176
0.010
Why?
Immunohistochemistry
1
2003
365
0.010
Why?
Venugopal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (236)
Explore
_
Co-Authors (19)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_